Video

Dr. Ahn on Choosing Between Treatment Options in CLL

Author(s):

Inhye Ahn, MD, physician, discusses choosing between treatment options in chronic lymphocytic leukemia.

Inhye Ahn, MD, physician, Dana-Farber Cancer Institute, faculty of Medicine, Harvard Medical School, discusses choosing between treatment options in chronic lymphocytic leukemia (CLL).

Fixed-duration therapy or continuous therapy can be considered for most patients with CLL, Ahn says. When deciding on the best approach for an individual patient, factors to inform that decision include prior treatment status, patient preference, and adverse effects of each agent, Ahn says. Cardiovascular AEs are associated with BTK inhibitors, making it important to understand if a patient has a history of cardiovascular disease, Ahn explains.

If patients prefer to not take medication daily, this can also affect treatment decisions, since a venetoclax (Venclexta)-based regimen could be preferable over a daily BTK inhibitor, Ahn concludes.

Related Videos
Yair Lotan, MD, UT Southwestern Medical Center
Alan Tan, MD, Vanderbilt-Ingram Cancer Center
Alex Herrera, MD
Roy S. Herbst, MD, PhD
Sheldon M. Feldman, MD
Laura J. Chambers, DO
Thomas Westbrook, MD
Massimo Cristofanilli, MD, attending physician, NewYork-Presbyterian Hospital; professor, medicine, Weill Cornell Medical College, Cornell University
Fred Saad, CQ, MD, FRCS, FCAHS, director, Prostate Cancer Research, Montreal Cancer Institute, Centre Hospitalier de l’Université de Montréal; full professor, Department of Surgery, Université de Montréal; uro-oncologist, Urology Department, University of Montreal Health Center
Ajay K. Nooka, MD, MPH, FACP